Apyx Medical (APYX) Cost of Revenue (2011 - 2026)

Apyx Medical (APYX) has reported Cost of Revenue for 16 consecutive years, with $5.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 16.88% year-over-year to $5.0 million; the trailing twelve-month figure through Jun 2026 stood at $21.3 million (up 19.49% YoY), and the FY2025 full-year result was $19.8 million, up 5.65% from the prior year.
• Cost of Revenue rose to $5.0 million in Q2 2026 per APYX's latest filing, from $4.6 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $7.2 million in Q4 2025 and bottomed at $3.4 million in Q3 2022.
• Historically, Cost of Revenue has averaged $4.6 million across 5 years, with a median of $4.5 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue soared 53.85% in 2022, then decreased 12.34% in 2025.
• Over 5 years, Cost of Revenue stood at $4.4 million in 2022, then jumped by 31.19% to $5.7 million in 2023, then slipped by 8.29% to $5.3 million in 2024, then soared by 36.27% to $7.2 million in 2025, then slumped by 30.02% to $5.0 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $5.0 million, $4.6 million, and $7.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.